Skip to content
Screener

Celcuity CELC Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Eli Lilly logo
Eli LillyLLY
$7.48B+20.2%
Gilead Sciences logo
Gilead SciencesGILD
$4.75B+17.9%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$20.12M+11.1%
Immunome logo
ImmunomeIMNM
$5.42M+24.6%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$31K-44.6%
Oric Pharmaceuticals, Inc. logo
Oric Pharmaceuticals, Inc.ORIC

Other financials

Income statement

See full
Operating income-$50.5M-39.8%
Net income-$52.8M-42.8%
EPS (diluted)-$0.97-12.8%

Balance sheet

See full
Cash & equivalents$145.2M+781%
Total debt$137.9M+30.7%
Total equity$53.5M-38.2%
Total assets$410.2M+88.0%

Cash flow

See full
Operating cash flow-$55.1M-53.6%
CapEx$249.0K+315%
Free cash flow-$55.3M-54.0%

Valuation

See full
Market cap$4.43B+131%
Enterprise value$4.42B+124%

Returns & leverage

See full
Return on equity-275.2%-990pp
Debt / equity2.6×+1.4×
Current ratio12.3×+5.7×

Where this comes from

Reported directly by Celcuity in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The source filing: Celcuity’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 5:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001493152-26-023180
Line itemMarch 31, 2026December 31, 2025
Total current assets408,929465,659
Property and equipment, net619499
Operating lease right-of-use assets1351
Other non-current assets603349
Total assets$410,164$466,558
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$10,454$6,407

Item 1. Financial Statements (unaudited) ITEM

FAQ

What is Celcuity's deferred tax assets and other non-current assets?
Celcuity (CELC) reported deferred tax assets and other non-current assets of $603K in Q1 2026.

Ask your AI about Celcuity's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude